Hyperlipoproteinemia Type II

"Hyperlipoproteinemia Type II" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

A group of familial disorders characterized by elevated circulating cholesterol contained in either LOW-DENSITY LIPOPROTEINS alone or also in VERY-LOW-DENSITY LIPOPROTEINS (pre-beta lipoproteins).

Descriptor ID	D006938
MeSH Number(s)	C16.320.565.398.481 C18.452.584.500.500.644.475 C18.452.648.398.481
Concept/Terms	Hyperlipoproteinemia Type II Hyperlipoproteinemia Type II Hyperlipoproteinemia Type IIs Hyper-Low Density Lipoproteinemia Density Lipoproteinemia, Hyper-Low Density Lipoproteinemias, Hyper-Low Hyper Low Density Lipoproteinemia Hyper-Low Density Lipoproteinemias Lipoproteinemia, Hyper-Low Density Lipoproteinemias, Hyper-Low Density Hyper-Low-Density-Lipoproteinemia Hyper-Low-Density-Lipoproteinemias Hyperlipoproteinemia, Type II Hyperlipoproteinemias, Type II Type II Hyperlipoproteinemia Type II Hyperlipoproteinemias Hypercholesterolemia, Essential Essential Hypercholesterolemia Essential Hypercholesterolemias Hypercholesterolemias, Essential Hypercholesterolemia, Familial Familial Hypercholesterolemia Familial Hypercholesterolemias Hypercholesterolemias, Familial Hypercholesterolemic Xanthomatosis, Familial Familial Hypercholesterolemic Xanthomatoses Familial Hypercholesterolemic Xanthomatosis Hypercholesterolemic Xanthomatoses, Familial Xanthomatoses, Familial Hypercholesterolemic Xanthomatosis, Familial Hypercholesterolemic Hyperlipoproteinemia Type 2 Hyperlipoproteinemia Type 2s Type 2, Hyperlipoproteinemia Hyper-beta-Lipoproteinemia Hyper beta Lipoproteinemia Hyper-beta-Lipoproteinemias Hyperbetalipoproteinemia Hyperbetalipoproteinemias Hyperlipoproteinemia Type IIb Hyperlipoproteinemia Type IIb Hyperlipoproteinemia Type IIbs Hypercholesterolemia, Autosomal Dominant, Type B Familial Combined Hyperlipoproteinemia Combined Hyperlipoproteinemia, Familial Combined Hyperlipoproteinemias, Familial Familial Combined Hyperlipoproteinemias Hyperlipoproteinemia, Familial Combined Hyperlipoproteinemias, Familial Combined Apolipoprotein B-100, Familial Defective Apolipoprotein B 100, Familial Defective Apolipoprotein B-100, Familial Ligand-Defective Apolipoprotein B 100, Familial Ligand Defective Hyperlipoproteinemia Type IIa Hyperlipoproteinemia Type IIa Hyperlipoproteinemia Type IIas Hyperlipoproteinemia, Type IIa Hyperlipoproteinemias, Type IIa Type IIa Hyperlipoproteinemia Type IIa Hyperlipoproteinemias Hypercholesterolemia, Autosomal Dominant Autosomal Dominant Hypercholesterolemia Autosomal Dominant Hypercholesterolemias Dominant Hypercholesterolemia, Autosomal Dominant Hypercholesterolemias, Autosomal Hypercholesterolemias, Autosomal Dominant LDL Receptor Disorder Disorder, LDL Receptor Disorders, LDL Receptor LDL Receptor Disorders Receptor Disorder, LDL Receptor Disorders, LDL

Below are MeSH descriptors whose meaning is more general than "Hyperlipoproteinemia Type II".

Diseases [C]
Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
Genetic Diseases, Inborn [C16.320]
Metabolism, Inborn Errors [C16.320.565]
Lipid Metabolism, Inborn Errors [C16.320.565.398]
Hyperlipoproteinemia Type II [C16.320.565.398.481]
Nutritional and Metabolic Diseases [C18]
Metabolic Diseases [C18.452]
Lipid Metabolism Disorders [C18.452.584]
Dyslipidemias [C18.452.584.500]
Hyperlipidemias [C18.452.584.500.500]
Hyperlipoproteinemias [C18.452.584.500.500.644]
Hyperlipoproteinemia Type II [C18.452.584.500.500.644.475]
Metabolism, Inborn Errors [C18.452.648]
Lipid Metabolism, Inborn Errors [C18.452.648.398]
Hyperlipoproteinemia Type II [C18.452.648.398.481]

Below are MeSH descriptors whose meaning is related to "Hyperlipoproteinemia Type II".

Below are MeSH descriptors whose meaning is more specific than "Hyperlipoproteinemia Type II".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Hyperlipoproteinemia Type II" by people in this website by year, and whether "Hyperlipoproteinemia Type II" was a major or minor topic of these publications.

Bar chart showing 64 publications over 17 distinct years, with a maximum of 7 publications in 2017 and 2020

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1996	0	1	1
1998	1	0	1
2010	1	0	1
2011	3	0	3
2012	1	0	1
2013	2	0	2
2014	3	0	3
2015	3	0	3
2016	6	0	6
2017	7	0	7
2018	4	1	5
2019	5	0	5
2020	7	0	7
2021	5	0	5
2022	6	0	6
2023	4	0	4
2024	4	0	4

Below are the most recent publications written about "Hyperlipoproteinemia Type II" by people in Profiles.

Gidding SS, Ballantyne CM, Cuchel M, de Ferranti S, Hudgins L, Jamison A, McGowan MP, Peterson AL, Steiner RD, Uveges MK, Wang Y. It is Time to Screen for Homozygous Familial Hypercholesterolemia in the United States. Glob Heart. 2024; 19(1):43.

View in: PubMed
Jones LK, Gidding SS, Santos RD, Libby P, Watts GF, Sarkies MN. Application of implementation science for improving the utilization of an international clinical practice guidance on familial hypercholesterolemia. J Clin Lipidol. 2024 Jul-Aug; 18(4):e525-e536.

View in: PubMed
Watts GF, Jones LK, Sarkies MN, Pang J, Gidding SS, Libby P, Santos RD. International Atherosclerosis Society Roadmap for Familial Hypercholesterolaemia. Glob Heart. 2024; 19(1):12.

View in: PubMed
Jones LK, Romagnoli KM, Schubert TJ, Clegg K, Kirchner HL, Hu Y, Cawley D, Norelli V, Williams MS, Gidding SS, Rahm AK. Using implementation science to develop a familial hypercholesterolemia screening program in primary care: The CARE-FH study. J Clin Lipidol. 2024 Mar-Apr; 18(2):e176-e188.

View in: PubMed
Gidding SS. Childhood Screening for Familial?Hypercholesterolemia: JACC Review Topic of the Week. J Am Coll Cardiol. 2023 10 10; 82(15):1558-1563.

View in: PubMed
Berry ASF, Jones LK, Sijbrands EJ, Gidding SS, Oetjens MT. Subtyping Severe Hypercholesterolemia by Genetic Determinant to Stratify Risk of Coronary Artery Disease. Arterioscler Thromb Vasc Biol. 2023 10; 43(10):2058-2067.

View in: PubMed
Gidding SS, Kirchner HL, Brangan A, Howard W, Kelly MA, Myers KD, Morgan KM, Oetjens MT, Shuey TC, Staszak D, Strande NT, Walters NL, Yu KD, Wilemon KA, Williams MS, Sturm AC, Jones LK. Yield of Familial Hypercholesterolemia Genetic and Phenotypic Diagnoses After Electronic Health Record and Genomic Data Screening. J Am Heart Assoc. 2023 07 04; 12(13):e030073.

View in: PubMed
Watts GF, Gidding SS, Hegele RA, Raal FJ, Sturm AC, Jones LK, Sarkies MN, Al-Rasadi K, Blom DJ, Daccord M, de Ferranti SD, Folco E, Libby P, Mata P, Nawawi HM, Ramaswami U, Ray KK, Stefanutti C, Yamashita S, Pang J, Thompson GR, Santos RD. International Atherosclerosis Society guidance for implementing best practice in the care of familial hypercholesterolaemia. Nat Rev Cardiol. 2023 12; 20(12):845-869.

View in: PubMed
Gidding SS, Wiegman A, Groselj U, Freiberger T, Peretti N, Dharmayat KI, Daccord M, Bedlington N, Sikonja J, Ray KK, Santos RD, Halle M, Tokg?zoglu L, Guti?rrez-Ibarluzea I, Pinto FJ, Geanta M. Paediatric familial hypercholesterolaemia screening in Europe: public policy background and recommendations. Eur J Prev Cardiol. 2022 12 21; 29(18):2301-2311.

View in: PubMed
Gidding SS, Hegele RA. Introducing Personalized Medicine Into Pediatric Homozygous Familial Hypercholesterolemia Care. Arterioscler Thromb Vasc Biol. 2022 12; 42(12):1458-1460.

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement